237 related articles for article (PubMed ID: 29566171)
21. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.
Servais A; Frémeaux-Bacchi V; Lequintrec M; Salomon R; Blouin J; Knebelmann B; Grünfeld JP; Lesavre P; Noël LH; Fakhouri F
J Med Genet; 2007 Mar; 44(3):193-9. PubMed ID: 17018561
[TBL] [Abstract][Full Text] [Related]
22. C3 glomerulopathy: what's in a name?
D'Agati VD; Bomback AS
Kidney Int; 2012 Aug; 82(4):379-81. PubMed ID: 22846813
[TBL] [Abstract][Full Text] [Related]
23. High-Throughput Genetic Testing for Thrombotic Microangiopathies and C3 Glomerulopathies.
Bu F; Borsa NG; Jones MB; Takanami E; Nishimura C; Hauer JJ; Azaiez H; Black-Ziegelbein EA; Meyer NC; Kolbe DL; Li Y; Frees K; Schnieders MJ; Thomas C; Nester C; Smith RJ
J Am Soc Nephrol; 2016 Apr; 27(4):1245-53. PubMed ID: 26283675
[TBL] [Abstract][Full Text] [Related]
24. C3 glomerulonephritis secondary to mutations in factors H and I: rapid recurrence in deceased donor kidney transplant effectively treated with eculizumab.
Garg N; Zhang Y; Nicholson-Weller A; Khankin EV; Borsa NG; Meyer NC; McDermott S; Stillman IE; Rennke HG; Smith RJ; Pavlakis M
Nephrol Dial Transplant; 2018 Dec; 33(12):2260-2265. PubMed ID: 29370420
[TBL] [Abstract][Full Text] [Related]
25. Kidney Transplantation in C3 Glomerulopathy: A Case Series.
Regunathan-Shenk R; Avasare RS; Ahn W; Canetta PA; Cohen DJ; Appel GB; Bomback AS
Am J Kidney Dis; 2019 Mar; 73(3):316-323. PubMed ID: 30413277
[TBL] [Abstract][Full Text] [Related]
26. [Changes in the complement system in membranoproliferative glomerulonephritis].
Yurova VA; Bobrova LA; Kozlovskaya NL; Korotchaeva YV; Serova AG; Kozlov LV; Andina SS; Demyanova KA; Kuchieva AM; Roshchupkina SV
Ter Arkh; 2017; 89(6):69-77. PubMed ID: 28745692
[TBL] [Abstract][Full Text] [Related]
27. C3 glomerulonephritis with a severe crescentic phenotype.
Ravindran A; Fervenza FC; Smith RJH; Sethi S
Pediatr Nephrol; 2017 Sep; 32(9):1625-1633. PubMed ID: 28593446
[TBL] [Abstract][Full Text] [Related]
28. Apolipoprotein E is enriched in dense deposits and is a marker for dense deposit disease in C3 glomerulopathy.
Madden B; Singh RD; Haas M; Palma LMP; Sharma A; Vargas MJ; Gross L; Negron V; Nate T; Charlesworth MC; Theis JD; Nasr SH; Nath KA; Fervenza FC; Sethi S
Kidney Int; 2024 May; 105(5):1077-1087. PubMed ID: 38447879
[TBL] [Abstract][Full Text] [Related]
29. Long-term follow-up including extensive complement analysis of a pediatric C3 glomerulopathy cohort.
Michels MAHM; Wijnsma KL; Kurvers RAJ; Westra D; Schreuder MF; van Wijk JAE; Bouts AHM; Gracchi V; Engels FAPT; Keijzer-Veen MG; Dorresteijn EM; Volokhina EB; van den Heuvel LPWJ; van de Kar NCAJ
Pediatr Nephrol; 2022 Mar; 37(3):601-612. PubMed ID: 34476601
[TBL] [Abstract][Full Text] [Related]
30. C3 glomerulopathy: the genetic and clinical findings in dense deposit disease and C3 glomerulonephritis.
Xiao X; Pickering MC; Smith RJ
Semin Thromb Hemost; 2014 Jun; 40(4):465-71. PubMed ID: 24799308
[TBL] [Abstract][Full Text] [Related]
31. Morphological and etiological analyses of C3 and non-C3 glomerulonephritis in primary membranoproliferative glomerulonephritis using periodic acid-methenamine silver stain electron microscopy: a retrospective multicentered study.
Honma S; Sato N; Sakaguchi R; Hashiguchi A; Uesugi N; Nakamura Y; Sasano H; Joh K
Med Mol Morphol; 2024 Mar; 57(1):23-34. PubMed ID: 37823929
[TBL] [Abstract][Full Text] [Related]
32. Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion.
Sethi S; Nester CM; Smith RJ
Kidney Int; 2012 Mar; 81(5):434-41. PubMed ID: 22157657
[TBL] [Abstract][Full Text] [Related]
33. Histopathology of MPGN and C3 glomerulopathies.
Cook HT; Pickering MC
Nat Rev Nephrol; 2015 Jan; 11(1):14-22. PubMed ID: 25447133
[TBL] [Abstract][Full Text] [Related]
34. Genetic abnormalities in biopsy-proven, adult-onset hemolytic uremic syndrome and C3 glomerulopathy.
Haydock L; Garneau AP; Tremblay L; Yen HY; Gao H; Harrisson R; Isenring P
J Mol Med (Berl); 2022 Feb; 100(2):269-284. PubMed ID: 34714369
[TBL] [Abstract][Full Text] [Related]
35. C3 Glomerulopathy: Pathogenesis and Treatment.
Ahmad SB; Bomback AS
Adv Chronic Kidney Dis; 2020 Mar; 27(2):104-110. PubMed ID: 32553242
[TBL] [Abstract][Full Text] [Related]
36. Use of C4d as a diagnostic tool to classify membranoproliferative glomerulonephritis.
Gupta N; Wakefield DN; Clapp WL; Garin EH
Nefrologia; 2017; 37(1):78-86. PubMed ID: 27595516
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic and Prognostic Comparison of Immune-Complex-Mediated Membranoproliferative Glomerulonephritis and C3 Glomerulopathy.
Kovala M; Seppälä M; Räisänen-Sokolowski A; Meri S; Honkanen E; Kaartinen K
Cells; 2023 Feb; 12(5):. PubMed ID: 36899849
[TBL] [Abstract][Full Text] [Related]
38. Therapy and outcomes of C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis.
Khandelwal P; Bhardwaj S; Singh G; Sinha A; Hari P; Bagga A
Pediatr Nephrol; 2021 Mar; 36(3):591-600. PubMed ID: 32886193
[TBL] [Abstract][Full Text] [Related]
39. C3 glomerulopathy and current dilemmas.
Ito N; Ohashi R; Nagata M
Clin Exp Nephrol; 2017 Aug; 21(4):541-551. PubMed ID: 27878657
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
